Literature DB >> 8570823

False positive tuberculosis skin test results.

J C Grabau1, G T DiFerdinando, L F Novick.   

Abstract

The re-emergence of tuberculosis as a significant public health threat has led to greatly renewed activity in tuberculin skin testing to identify infected persons. However, even use of the preferred skin test technique (intradermal injection of purified protein derivative via the Mantoux method) can lead to either false positive or false negative results. Interpretation of a Mantoux test can be influenced by cross reactions with other mycobacteria, intertester variation, host-response variation, and product related problems. At least 25 apparent false positive purified protein derivative skin test reactions in New York State in 1992 appeared to be associated with lots of the derivative produced by one manufacturer. These unexpected skin test results led to examination of a product with an altered appearance that may have caused the unanticipated responses. After announcement of these false positive results to the press, the company removed the product from the market. Food and Drug Administration analysis later revealed particulate matter in vials of the suspected lots of purified protein derivative.

Entities:  

Mesh:

Year:  1995        PMID: 8570823      PMCID: PMC1381812     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  11 in total

1.  Tuberculin testing in a tertiary hospital: product variability.

Authors:  J W Shands; D Boeff; L Fauerbach; R R Gutekunst
Journal:  Infect Control Hosp Epidemiol       Date:  1994-12       Impact factor: 3.254

Review 2.  The tuberculin skin test.

Authors:  R E Huebner; M F Schein; J B Bass
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

3.  A high false-positive rate of tuberculosis associated with Aplisol: an investigation among health care workers.

Authors:  B P Lanphear; C C Linnemann; C G Cannon
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

4.  Multidrug-resistant tuberculosis in the New York State prison system, 1990-1991.

Authors:  S E Valway; R B Greifinger; M Papania; J O Kilburn; C Woodley; G T DiFerdinando; S W Dooley
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

5.  False-positive results of Mantoux tests.

Authors:  J Mellor
Journal:  Can Med Assoc J       Date:  1985-06-15       Impact factor: 8.262

6.  Tuberculin test. Variability with the Mantoux procedure.

Authors:  S D Chaparas; H M Vandiviere; I Melvin; G Koch; C Becker
Journal:  Am Rev Respir Dis       Date:  1985-07

7.  Nationwide survey of drug-resistant tuberculosis in the United States.

Authors:  A B Bloch; G M Cauthen; I M Onorato; K G Dansbury; G D Kelly; C R Driver; D E Snider
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

Review 8.  Tuberculosis symposium: emerging problems and promise.

Authors:  J J Ellner; A R Hinman; S W Dooley; M A Fischl; K A Sepkowitz; M J Goldberger; T M Shinnick; M D Iseman; W R Jacobs
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

9.  The emergence of drug-resistant tuberculosis in New York City.

Authors:  T R Frieden; T Sterling; A Pablos-Mendez; J O Kilburn; G M Cauthen; S W Dooley
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245

10.  Discrepancies in tuberculin skin test results with two commercial products in a population of intravenous drug users.

Authors:  A R Lifson; J K Watters; S Thompson; C M Crane; F Wise
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

View more
  2 in total

1.  Performance of Loop-Mediated Isothermal Amplification Technique in Milk Samples for the Diagnosis of Bovine Tuberculosis in Dairy Cattle Using a Bayesian Approach.

Authors:  Tawatchai Singhla; Surachai Pikulkaew; Sukolrat Boonyayatra
Journal:  Pathogens       Date:  2022-05-12

2.  16 kDa heat shock protein from heat-inactivated Mycobacterium tuberculosis is a homodimer - suitability for diagnostic applications with specific llama VHH monoclonals.

Authors:  Saurabh K Srivastava; Vincent J B Ruigrok; Natalie J Thompson; Anke K Trilling; Albert J R Heck; Cees van Rijn; Jules Beekwilder; Maarten A Jongsma
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.